Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer

Archivum Immunologiae et Therapiae Experimentalis

Volumn 57, Issue 6, 2009, Pages 409-423

  Chentoufi, Aziz Alami ^a   Nesburn, Anthony B ^a   Benmohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Epitopes; Glycolipopeptide; T cell; TLR; Vaccine

Indexed keywords

CANCER VACCINE; EPITOPE; PEPTIDE VACCINE; TOLL LIKE RECEPTOR; TRASTUZUMAB; TUMOR ANTIGEN;

BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; REVIEW; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; GLYCOLIPIDS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; PEPTIDE FRAGMENTS;

EID: 70450237650     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-009-0049-2     Document Type: Review

References (148)

1. AL Ackerman P Cresswell 2004 Cellular mechanisms governing cross-presentation of exogenous antigens Nat Immunol 5 678 684 15224093
2. JD Ahlers IM Belyakov S Matsui, et al. 2001 Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-alpha synergize for IL-12R expression at low antigen dose Int Immunol 13 1433 1442 11675375
3. M Ahmadzadeh SA Rosenberg 2006 IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients Blood 107 2409 2414 16304057
4. V Apostolopoulos DS Pouniotis PJ van Maanen, et al. 2006 Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses Vaccine 24 3191 3202 16480791
5. E Appella DJ Loftus K Sakaguchi, et al. 1995 Synthetic antigenic peptides as a new strategy for immunotherapy of cancer Biomed Pept Proteins Nucleic Acids 1 177 184 9346850
6. A Astolfi S Rolla P Nanni E Quaglino, et al. 2005 Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario Cancer Immunol Immunother 54 599 610 15690207
7. DL Barber EJ Wherry D Masopust, et al. 2006 Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 682 687 16382236
8. K Bartnes K Hannestad G Guichard, et al. 1997 A retroinverso analog mimics the cognate peptide epitope of a CD4+ T cell clone Eur J Immunol 27 1387 1391 9209489
9. CN Baxevanis NN Sotiriadou AD Gritzapis, et al. 2006 Immunogenic HER-2/neu peptides as tumor vaccines Cancer Immunol Immunother 55 85 95 15948002
10. L BenMohamed Y Belkaid E Loing, et al. 2002 Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant Eur J Immunol 32 2274 2281 12209640
11. L BenMohamed H Gras-Masse A Tartar, et al. 1997 Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees Eur J Immunol 27 1242 1253 9174617
12. L BenMohamed R Krishnan C Auge, et al. 2002 Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses Immunology 106 113 121 11972639
13. L BenMohamed R Krishnan J Longmate, et al. 2000 Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response Hum Immunol 61 764 779 10980387
14. L BenMohamed A Thomas M Bossus, et al. 2000 High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules Vaccine 18 2843 2855 10812228
15. L BenMohamed SL Wechsler AB Nesburn 2002 Lipopeptide vaccines - yesterday, today, and tomorrow Lancet Infect Dis 2 425 431 12127354
16. SR Bennett FR Carbone F Karamalis, et al. 1998 Help for cytotoxic-T-cell responses is mediated by CD40 signalling Nature 393 478 480 9624004
17. T Ben-Yedidia AS Beignon CD Partidos, et al. 2002 A retroinverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization Mol Immunol 39 323 331 12220890
18. JA Berzofsky JD Ahlers IM Belyakov 2001 Strategies for designing and optimizing new generation vaccines Nat Rev Immunol 1 209 219 11905830
19. JA Berzofsky M Terabe S Oh, et al. 2004 Progress on new vaccine strategies for the immunotherapy and prevention of cancer J Clin Invest 113 1515 1525 15173875 (Pubitemid 39071672)
20. I Bettahi G Dasgupta O Renaudet, et al. 2009 Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4(+) and CD8 (+) T cell epitopes Cancer Immunol Immunother 58 187 200 18584174
21. I Bettahi AB Nesburn S Yoon, et al. 2007 Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines Invest Ophthalmol Vis Sci 48 4643 4653 17898288
22. I Bettahi X Zhang RE Afifi, et al. 2006 Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response Viral Immunol 19 220 236 16817765
23. M Beyer M Kochanek K Darabi, et al. 2005 Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 106 2018 2025 15914560
24. M Beyer JL Schultze 2006 Regulatory T cells in cancer Blood 108 804 811 16861339
25. JN Blattman PD Greenberg 2004 Cancer immunotherapy: a treatment for the masses Science 305 200 205 15247469
26. D Boturyn JL Coll E Garanger, et al. 2004 Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis J Am Chem Soc 126 5730 5739 15125666
27. JM Burchell A Mungul J Taylor-Papadimitriou 2001 O-linked glycosylation in the mammary gland: changes that occur during malignancy J Mammary Gland Biol Neoplasia 6 355 364 11547903
28. R Busch A Pashine KC Garcia, et al. 2002 Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers J Immunol Methods 263 111 121 12009208
29. T Buskas S Ingale GJ Boons 2005 Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen Angew Chem Int Ed Engl 44 5985 5988 16108081
30. SA Byron D Yee 2003 Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer Semin Oncol 30 125 132 14613033 (Pubitemid 37433403)
31. Y Cao P Stosiek GF Springer, et al. 1996 Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study Histochem Cell Biol 106 197 207 8877380
32. GC Cesana G DeRaffele S Cohen, et al. 2006 Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma J Clin Oncol 24 1169 1177 16505437
33. F Cheng HW Wang A Cuenca, et al. 2003 A critical role for Stat3 signaling in immune tolerance Immunity 19 425 436 14499117
34. RA Clynes TL Towers LG Presta, et al. 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446 10742152
35. A Coutinho I Caramalho E Seixas, et al. 2005 Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection Curr Top Microbiol Immunol 293 43 71 15981475
36. MV Croce MT Isla-Larrain CE Rua, et al. 2003 Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer J Histochem Cytochem 51 781 788 12754289
37. TJ Curiel G Coukos L Zou, et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 15322536
38. G Curigliano G Spitaleri E Pietri, et al. 2006 Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 17 750 762 16293674
39. ML Disis E Calenoff G McLaughlin, et al. 1994 Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer Cancer Res 54 16 20 7505195
40. ML Disis MA Cheever 1996 Oncogenic proteins as tumor antigens Curr Opin Immunol 8 637 642 8902388
41. ML Disis MA Cheever 1997 HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer Adv Cancer Res 71 343 371 9111870
42. D Dodwell D Williamson 2002 GM-CSF-based cancer vaccines Immunol Rev 188 147 154
43. G Dranoff 2008 Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer Cancer Treat Rev 34 137 144
44. A Eastman JR Rigas 1999 Modulation of apoptosis signaling pathways and cell cycle regulation Semin Oncol 26 7 16 10585003 discussion 41-42
45. SA Eccles 2005 Targeting key steps in metastatic tumour progression Curr Opin Genet Dev 15 77 86 15661537
46. AM Ercolini BH Ladle EA Manning 2005 Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 201 1591 1602 15883172
47. R Essner M Kojima 2002 Dendritic cell function in sentinel nodes Oncology 16 27 31 11829280
48. OJ Finn 2003 Cancer vaccines: between the idea and the reality Nat Rev Immunol 3 630 641 12974478
49. B Fisher S Anderson J Bryant, et al. 2002 Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer N Engl J Med 347 1233 1241 12393820
50. A Franco 2005 CTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens Scand J Immunol 61 391 397 15882430
51. GJ Freeman AH Sharpe VK Kuchroo 2002 Protect the killer: CTLs need defenses against the tumor Nat Med 8 787 789 12152031
52. EJ Fuchs P Matzinger 1996 Is cancer dangerous to the immune system? Semin Immunol 8 271 280 8956455
53. S Gallucci M Lolkema P Matzinger 1999 Natural adjuvants: endogenous activators of dendritic cells Nat Med 5 1249 1255 10545990
54. KA Gelderman S Tomlinson GD Ross, et al. 2004 Complement function in mAb-mediated cancer immunotherapy Trends Immunol 25 158 164 15036044
55. RK Gershon 1975 A disquisition on suppressor T cells Transplant Rev 26 170 185 1101469
56. H Ghebeh E Barhoush A Tulbah, et al. 2008 FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy BMC Cancer 8 57 18294387
57. A Girling J Bartkova J Burchell, et al. 1989 A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas Int J Cancer 43 1072 1076 2471698
58. TS Gourley EJ Wherry D Masopust, et al. 2004 Generation and maintenance of immunological memory Semin Immunol 16 323 333 15528077
59. S Grigalevicius S Chierici O Renaudet, et al. 2005 Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines Bioconjug Chem 16 1149 1159 16173792
60. AD Gritzapis LG Mahaira SA Perez, et al. 2006 Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo Cancer Res 66 5452 5460 16707474
61. AD Gritzapis IF Voutsas E Lekka, et al. 2008 Identification of a novel immunogenic HLA-A*0201-binding epitope of HER- 2/neu with potent antitumor properties J Immunol 181 146 154 18566379
62. S Hakomori 2001 Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines Adv Exp Med Biol 491 369 402 14533809
63. CJ Hertz SM Kiertscher PJ Godowski, et al. 2001 Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2 J Immunol 166 2444 2450 11160304
64. HE Heslop CY Ng C Li, et al. 1996 Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes Nat Med 2 551 555 8616714
65. B Homey A Muller A Zlotnik 2002 Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2 175 184 11913068
66. L Huang D Chen D Liu, et al. 2005 MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin Cancer Res 65 10413 10422 16288032
67. RR Huang DR Wen J Guo, et al. 2000 Selective modulation of paracortical dendritic cells and T-Lymphocytes in breast cancer sentinel lymph nodes Breast J 6 225 232 11348370
68. M Ito Y Minamiya H Kawai, et al. 2006 Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node J Immunol 176 5637 5643 16622033
69. CA Janeway Jr R Medzhitov 1999 Lipoproteins take their toll on the host Curr Biol 9 R879 882 10607553
70. H Kao JA Marto TK Hoffmann, et al. 2001 Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells J Exp Med 194 1313 1323 11696596
71. ME Keir MJ Butte GJ Freeman, et al. 2008 PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677 704 18173375
72. BK Ko K Kawano JL Murray, et al. 2003 Clinical studies of vaccines targeting breast cancer Clin Cancer Res 9 3222 3234 12960107
73. A Kondo J Sidney S Southwood, et al. 1997 Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes Immunogenetics 45 249 258 9002445
74. K Kono H Kawaida A Takahashi, et al. 2006 CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers Cancer Immunol Immunother 55 1064 1071 16328385
75. K Kontani O Taguchi Y Ozaki, et al. 2003 Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin Int J Mol Med 12 493 502 12964025
76. AM Krensky C Clayberger CS Reiss, et al. 1982 Specificity of OKT4+ cytotoxic T lymphocyte clones J Immunol 129 2001 2003 6181153
77. A Krug S Rothenfusser S Selinger, et al. 2003 CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells J Immunol 170 3468 3477 12646607
78. LF Langer TM Clay MA Morse 2007 Update on antiCTLA-4 antibodies in clinical trials Expert Opin Biol Ther 7 1245 1256 17696822
79. PJ Lehner P Cresswell 2004 Recent developments in MHC-class-I-mediated antigen presentation Curr Opin Immunol 16 82 89 14734114
80. JY Liu XS Zhang Y Ding, et al. 2005 The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice J Transl Med 3 5 15679891
81. UK Liyanage TT Moore HG Joo, et al. 2002 Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 2756 2761 12193750
82. PL Lollini G Forni 2003 Cancer immunoprevention: tracking down persistent tumor antigens Trends Immunol 24 62 66 12547501
83. R Lo-Man S Vichier-Guerre R Perraut, et al. 2004 A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates Cancer Res 64 4987 4994 15256473
84. A Lundqvist A Choudhury T Nagata, et al. 2002 Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis Hum Gene Ther 13 1541 1549 12228009
85. A Margalit HM Sheikhet Y Carmi, et al. 2006 Induction of antitumor immunity by CTL epitopes genetically linked to membrane-anchored beta2-microglobulin J Immunol 176 217 224 16365413
86. FM Marincola EM Jaffee DJ Hicklin, et al. 2000 Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv Immunol 74 181 273 10605607
87. MA Markiewicz WM Kast 2004 Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes Cancer Invest 22 417 434 15493363
88. CE Marroquin JA Westwood R Lapointe, et al. 2002 Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells J Immunother 25 278 288 12000870
89. R Medzhitov 2001 CpG DNA: security code for host defense Nat Immunol 2 15 16 11135571
90. EA Mittendorf GE Peoples SE Singletary 2007 Breast cancer vaccines: promise for the future or pipe dream? Cancer 110 1677 1686 17763371
91. B Monzavi-Karbassi G Cunto-Amesty P Luo, et al. 2001 Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses Int Immunol 13 1361 1371 11675368
92. FO Nestle J Banchereau D Hart 2001 Dendritic cells: On the move from bench to bedside Nat Med 7 761 765 11433329
93. L Novellino C Castelli G Parmiani 2005 A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207 15309328
94. RA Oldenburg H Meijers-Heijboer CJ Cornelisse, et al. 2007 Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol Hematol 63 125 149 17498966
95. D O'Mahony JC Morris C Quinn, et al. 2007 A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin Cancer Res 13 958 964 17289891
96. RJ Orentas ME Kohler BD Johnson 2006 Suppression of anti-cancer immunity by regulatory T cells: back to the future Semin Cancer Biol 16 137 149 16376101
97. S Ostrand-Rosenberg P Sinha EA Danna, et al. 2004 Antagonists of tumor-specific immunity: tumor-induced immune suppression and host genes that co-opt the anti-tumor immune response Breast Dis 20 127 135 15687713
98. WW Overwijk MR Theoret SE Finkelstein, et al. 2003 Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 198 569 580 12925674
99. S Paik R Hazan R Fisher E, et al. 1990 Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 103 112 1967301
100. KS Peggs SA Quezada JP Allison 2008 Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy Immunol Rev 224 141 165 18759925
101. GE Peoples JP Holmes MT Hueman, et al. 2008 Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Clin Cancer Res 14 797 803 18245541
102. MJ Piccart-Gebhart M Procter B Leyland-Jones 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737
103. SJ Prasad KJ Farrand SA Matthews, et al. 2005 Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells J Immunol 174 90 98 15611231
104. G Ragupathi 1996 Carbohydrate antigens as targets for active specific immunotherapy Cancer Immunol Immunother 43 152 157 9001568
105. G Ragupathi NX Liu C Musselli, et al. 2005 Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity J Immunol 174 5706 5712 15843572
106. JJ Rahn JW Chow GJ Horne, et al. 2005 MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1 Clin Exp Metastasis 22 475 483 16320110
107. J Razkin V Josserand D Boturyn, et al. 2006 Activatable fluorescent probes for tumour-targeting imaging in live mice ChemMedChem 1 1069 1072 16944544
108. J Ren N Agata D Chen, et al. 2004 Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents Cancer Cell 5 163 175 14998492
109. N Renkvist C Castelli PF Robbins, et al. 2001 A listing of human tumor antigens recognized by T cells Cancer Immunol Immunother 50 3 15 11315507
110. O Renaudet L BenMohamed G Dasgupta, et al. 2008 Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine ChemMedChem 3 737 741 18205167
111. O Renaudet P Dumy 2003 Chemoselectively template- assembled glycoconjugates as mimics for multivalent presentation of carbohydrates Org Lett 5 243 246 12556162
112. SR Riddell 1995 Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts Semin Respir Infect 10 199 208 8668847
113. SR Riddell KS Watanabe JM Goodrich, et al. 1992 Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 257 238 241 1352912
114. JP Ridge F Di Rosa P Matzinger 1998 A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell Nature 393 474 478 9624003
115. SA Rosenberg JC Yang DJ Schwartzentruber, et al. 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 327 9500606
116. PA Ruffini A Biragyn LW Kwak 2002 Recent advances in multiple myeloma immunotherapy Biomed Pharmacother 56 129 132 12046683
117. RB Salit WM Kast MP Velders 2002 Ins and outs of clinical trials with peptide-based vaccines Front Biosci 7 e204 213 11991853
118. F Sallusto D Lenig R Forster, et al. 1999 Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 401 708 712 10537110
119. R Sangha C Butts 2007 L-BLP25: a peptide vaccine strategy in non small cell lung cancer Clin Cancer Res 13 s4652 4654 17671159
120. N Sato Y Nabeta H Kondo, et al. 2000 Human CD8 and CD4 T cell epitopes of epithelial cancer antigens Cancer Chemother Pharmacol 46 suppl S86 90 10950155
121. SP Schoenberger RE Toes EI van der Voort, et al. 1998 T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 480 483 9624005
122. Shankaran V, Ikeda H, Bruce AT (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1011
123. J Sidney MF del Guercio S Southwood, et al. 1995 Several HLA alleles share overlapping peptide specificities J Immunol 154 247 259 7527812
124. J Sidney HM Grey S Southwood, et al. 1996 Definition of an HLA-A3-like supermotif demonstrates the overlapping pep-tide-binding repertoires of common HLA molecules Hum Immunol 45 79 93 8882405
125. J Sidney S Southwood MF del Guercio, et al. 1996 Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules J Immunol 157 3480 3490 8871647
126. Y Singh O Renaudet E Defrancq, et al. 2005 Preparation of a multitopic glycopeptide-oligonucleotide conjugate Org Lett 7 1359 1362 15787506
127. SF Slovin SJ Keding G Ragupathi 2005 Carbohydrate vaccines as immunotherapy for cancer Immunol Cell Biol 83 418 428 16033538
128. EJ Small NS Tchekmedyian BI Rini, et al. 2007 A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 1810 1815 17363537
129. S Southwood J Sidney A Kondo, et al. 1998 Several common HLA-DR types share largely overlapping peptide binding repertoires J Immunol 160 3363 3373 9531296
130. DE Speiser R Miranda A Zakarian, et al. 1997 Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy J Exp Med 186 645 653 9271580
131. GF Springer 1997 Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy J Mol Med 75 594 602 9297627
132. MA Stene M Babajanians S Bhuta, et al. 1988 Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin J Invest Dermatol 91 125 128 3260930
133. RP Sutmuller MH den Brok M Kramer, et al. 2006 Toll-like receptor 2 controls expansion and function of regulatory T cells J Clin Invest 116 485 494 16424940
134. RP Sutmuller LM van Duivenvoorde A van Elsas, et al. 2001 Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J Exp Med 194 823 832 11560997
135. AH Tien L Xu CD Helgason 2005 Altered immunity accompanies disease progression in a mouse model of prostate dysplasia Cancer Res 65 2947 2955 15805298
136. JP Tite CA Janeway Jr 1984 Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis Eur J Immunol 14 878 886 6208035
137. SL Topalian MI Gonzales M Parkhurst, et al. 1996 Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes J Exp Med 183 1965 1971 8642306
138. TM Tuttle BW Anderson WE Thompson, et al. 1998 Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients Clin Cancer Res 4 2015 2024 9717833
139. T Umiel N Trainin 1974 Immunological enhancement of tumor growth by syngeneic thymus-derived lymphocytes Transplantation 18 244 250 4608685
140. S Vichier-Guerre R Lo-Man L BenMohamed, et al. 2003 Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anticancer vaccine for human use J Pept Res 62 117 124 12895273
141. S Vichier-Guerre R Lo-Man V Huteau, et al. 2004 Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen Bioorg Med Chem Lett 14 3567 3570 15177475
142. S von Mensdorff-Pouilly L Kinarsky K Engelmann, et al. 2005 Sequence-variant repeats of MUC1 show higher con- formational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses Glycobiology 15 735 746
143. CC Wang YL Huang CT Ren, et al. 2008 Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer Proc Natl Acad Sci USA 105 11661 11666 18689688
144. X Wei H Xu D Kufe 2005 Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response Cancer Cell 7 167 178 15710329
145. R Xu MA Perle G Inghirami, et al. 2002 Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material Mod Pathol 15 116 124 11850540
146. M Yasukawa JM Zarling 1984 Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities J Immunol 133 2736 2742 6207243
147. X Zhang A Issagholian EA Berg, et al. 2005 Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection J Virol 79 15289 15301 16306600
148. X Zhu TV Ramos H Gras-Masse, et al. 2004 Lipopeptide epitopes extanded by an Nepsilon-polmitoyl-lysine moiety increase uptake and maturation of dentritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity Eur J Immunol 34 3102 3114 15368273